Union Ministry of Health and Family Welfare Amends Drugs Rules, 1945; Exemption for Sale of Cough Syrups in Small Villages Withdrawn

1. At a Glance

• Ministry of Health and Family Welfare (MoHFW) amended the Drugs Rules, 1945 to remove the long-standing exemption that permitted over-the-counter (OTC) sale of cough syrups in villages with population < 1,000 without a licensed pharmacy [S1].
• Cough syrups now fall fully under the Drugs and Cosmetics Act, 1940 licensing regime — saleable only through duly licensed pharmacies, against valid prescriptions [S1][S3].
• Direct policy response to the 2025 India cough syrup crisis involving diethylene glycol (DEG) contamination flagged by the WHO Medical Product Alert N°5/2025 [S2][S4].
• Examinable as: GS-II (Health governance, regulation) and GS-III (Pharma sector, S&T safety).

2. Why in the News

• MoHFW notified Gazette Notification G.S.R. 927(E) dated 29 December 2025 (published 30 December 2025, Gazette of India Extraordinary, Part II, Section 3(i)) omitting the word "Syrup" from Schedule K, Serial No. 13, Entry 7 [S1].
• Triggered by child fatalities in Madhya Pradesh & Rajasthan linked to DEG-contaminated paediatric syrups (Coldrif, Respifresh TR, ReLife) in Sept–Oct 2025 [S2][S4].
• CDSCO reported DEG presence in at least three oral liquid medicines to WHO on 8 October 2025; WHO issued global alert on 13 October 2025 [S2][S4].

3. Background & Evolution

• Drugs and Cosmetics Act, 1940 + Drugs Rules, 1945 form the parent regulatory framework for manufacture, sale & distribution of drugs in India [S1].
• Schedule K lists drug classes exempt from certain provisions of the Act/Rules (e.g., licensing) [S1].
• Entry 13 historically allowed sale of certain household remedies — including syrups — in villages with population below 1,000 without a retail drug licence, to ensure rural access [S1][S3].
• 2019–2022: Earlier DEG/EG-contaminated Indian-made syrup incidents abroad (Gambia, Uzbekistan) prompted WHO alerts under Medical Product Alert N°6/2022 [S2].
• 2025: Domestic crisis in MP/Rajasthan prompted withdrawal of the village exemption [S2][S4].

4. Core Static Facts

• Parent Act: Drugs and Cosmetics Act, 1940 [S1].
• Parent Rules: Drugs Rules, 1945 [S1].
• Amendment vehicle: Gazette Notification G.S.R. 927(E), 29 Dec 2025 [S1].
• Affected provision: Schedule K, Serial No. 13, Entry 7 — word "Syrup" omitted [S1].
• Implementing Ministry: Union Ministry of Health and Family Welfare [S1].
• Regulator: Central Drugs Standard Control Organisation (CDSCO) under DGHS, MoHFW [S2].
• Population threshold for the erstwhile exemption: villages with population < 1,000 [S3].
• WHO alert reference: Medical Product Alert N°5/2025, dated 13 October 2025 [S4].
• Contaminant: Diethylene Glycol (DEG) — an industrial solvent; toxic effects: acute kidney injury, altered mental state, vomiting, anuria [S2].
• Implicated products: Coldrif (Sresan Pharmaceutical), Respifresh TR (Rednex Pharmaceuticals), ReLife (Shape Pharma) [S2].

5. Multi-Dimensional Analysis

Legal / Constitutional - Concurrent List subject — Entry 19 (Drugs and poisons), List III, Seventh Schedule governs centre-state powers over drugs. - Amendment uses delegated legislation power under Section 12 of the Drugs and Cosmetics Act, 1940 to amend Schedule K [S1]. - Tightens compliance with Right to Health (read into Article 21 by SC, e.g., Paschim Banga Khet Mazdoor Samity).

Administrative - Closes a rural regulatory gap that let unlicensed grocery/general stores sell syrups in small villages [S3]. - Shifts onus to state drug controllers to enforce licensing in last-mile rural retail. - Implementation challenge: ~6 lakh Indian villages, many with <1,000 population, may lose immediate access to OTC remedies.

Social / Public Health - Targets protection of paediatric population — primary victims of DEG poisoning [S2]. - May aggravate rural access deficit unless pharmacy networks (Jan Aushadhi Kendras) expand.

Scientific / Technological - DEG contamination arises from use of industrial-grade propylene glycol/glycerin instead of pharmaceutical grade — a QC/GMP failure under Schedule M [S2]. - Reinforces need for mandatory testing of excipients before formulation.

Geopolitical - India = "Pharmacy of the Global South"; prior DEG incidents (Gambia 2022, Uzbekistan 2022, Cameroon 2023) damaged export reputation [S2]. - WHO's 2025 alert ranks alongside earlier alerts, pushing India towards stricter domestic oversight [S4].

6. Recent Developments (last 12-18 months)

• 30 Sept 2025: WHO identifies clusters of paediatric fatalities in India [S2].
• 8 Oct 2025: CDSCO formally notifies WHO of DEG-contaminated syrups [S2].
• 13 Oct 2025: WHO issues Medical Product Alert N°5/2025 on substandard oral liquid medicines from India [S4].
• 29 Dec 2025: MoHFW notifies G.S.R. 927(E) amending Schedule K [S1].
• 30 Dec 2025: Amendment published in Gazette of India Extraordinary [S1].

7. Prelims Hooks

• Drugs Rules, 1945 are framed under the Drugs and Cosmetics Act, 1940 [S1].
• Schedule K = exemptions; Schedule H/H1 = prescription drugs; Schedule M = GMP norms (distinguish).
• Amendment instrument: G.S.R. 927(E) dated 29 December 2025 [S1].
• Word omitted from Schedule K Entry 13(7): "Syrup" [S1].
• Prior exemption population threshold: villages < 1,000 population [S3].
• Regulator: CDSCO, headed by Drugs Controller General of India (DCGI), under DGHS, MoHFW.
• Diethylene Glycol (DEG) — industrial solvent; not for human consumption [S2].
• WHO alert classification: Medical Product Alert N°5/2025 issued 13 Oct 2025 [S4].
• Drug regulation is in the Concurrent List (Entry 19, List III) of the Seventh Schedule.
• Sresan Pharmaceutical = manufacturer of Coldrif [S2].
• Jan Aushadhi Kendras — under Pharmaceuticals & Medical Devices Bureau of India (PMBI), Dept. of Pharmaceuticals (Ministry of Chemicals & Fertilizers) — not MoHFW.

8. Mains Relevance

• GS-II: Government policies and interventions for development in health; Issues relating to development and management of Social Sector — Health.
• GS-III: Science & Technology — indigenisation; Pharma sector; Issues relating to intellectual property and consumer safety.
• Possible question stems: 1. "Recurring incidents of diethylene-glycol contamination in Indian-made cough syrups expose systemic gaps in drug quality regulation. Examine the institutional and legal reforms needed to safeguard India's status as the 'Pharmacy of the World'." (GS-II/III, 15 marks) 2. "Critically evaluate the trade-off between rural access to medicines and pharmaceutical safety in light of the 2025 amendment to Schedule K of the Drugs Rules, 1945." (GS-II, 10 marks) 3. "Discuss the federal architecture of drug regulation in India and the role of CDSCO vis-à-vis State Drug Controllers." (GS-II, 10 marks)

9. Related Topics to Study Next

• CDSCO & DCGI — apex drug regulator structure.
• Schedule M (Revised GMP), 2024 — mandatory GMP for all manufacturers.
• Mashelkar Committee (2003) on spurious drugs — historical reform baseline.
• Jan Aushadhi (PMBJP) — affordable generics, rural access lever.
• PLI Scheme for Bulk Drugs/APIs — addresses upstream excipient quality.
• WHO Prequalification Programme — international quality benchmark.
• Pharmacy Act, 1948 — licences "registered pharmacists" who must dispense Sch H/H1 drugs.
• Article 47 (DPSP) — duty of State to raise nutrition and public health.

10. Common Errors / Trap Areas

• Wrong parent statute: It is the Drugs and Cosmetics Act, 1940, not the Pharmacy Act, 1948.
• Schedule confusion: Schedule K (exemptions) ≠ Schedule H/H1 (prescription) ≠ Schedule M (GMP) ≠ Schedule J (diseases that cannot be claimed to be cured).
• Wrong ministry: Regulation = MoHFW/CDSCO; pricing (NPPA) and Jan Aushadhi = Ministry of Chemicals & Fertilizers (Dept. of Pharmaceuticals).
• Population threshold: The exemption was for villages < 1,000, not 5,000 [S3].
• Contaminant identity: Diethylene Glycol (DEG) is distinct from Ethylene Glycol (EG); both are toxic but chemically separate.

11. Sources

• [S1] Union Ministry of Health and Family Welfare Amends Drugs Rules, 1945; Exemption for Sale of Cough Syrups in Small Villages Withdrawn — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2273373 — (tier: 1)
• [S2] Contaminated medicines affecting children — Q&A (WHO) — https://www.who.int/news-room/questions-and-answers/item/contaminated-medicines-affecting-children — (tier: 2)
• [S3] Steps taken to Prevent Sale of Adulterated Drugs (PIB) — https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2155448 — (tier: 1)
• [S4] Medical Product Alert N°5/2025: Substandard (contaminated) oral liquid medicines (WHO, 13 Oct 2025) — https://www.who.int/news/item/13-10-2025-medical-product-alert-n-5-2025--substandard-(contaminated)-oral-liquid-medicines — (tier: 2)